As Eli Lilly (NYSE: LLY) and Novo Nordisk (Nasdaq Copenhagen: NOVO-B) scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, a much smaller potential…
A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits membrane-associated tyrosine-threonine protein kinase 1 (PKMYT1, shown in…
Images of the scalps of two patients treated with the 5% formulation of Cosmo Pharmaceuticals’ androgenetic alopecia (AGA) candidate clascoterone—both during their first visits, and their seventh visits after six…
Protego Biopharma has completed a $130 million oversubscribed Series B financing that it said will help it advance its lead candidate, the amyloid light-chain (AL) amyloidosis treatment PROT-001, into a…
Lundbeck has ended its bidding war with Alkermes to acquire Avadel Pharmaceuticals, saying that it will not increase its offer for the sleep disorder drug developer beyond the approximately $2.4…
Five years after Alex Trebek shared publicly his diagnosis of stage IV metastatic pancreatic cancer, therapies for the disease remain few, and limited to specific patient subgroups. Metastatic pancreatic cancer…
More than two weeks after Pfizer (NYSE: PFE) and Novo Nordisk (NASDAQ Copenhagen: NOVO-B) slugged it out for Metsera (NASDAQ: MTSR), biopharma found itself in the grip of another bidding…
Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, then dropped on Thursday,…
Credit: TopMicrobialStock / Adobe Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis…
Hernan Bazan, MD, CEO and co-founder of South Rampart Pharma with Josh Blacher, MBA, chief financial officer. South Rampart Pharma is working to develop an oral small molecule non-opioid pain…